Eli Lilly and Company $LLY Shares Sold by Kayne Anderson Rudnick Investment Management LLC

Key Points

• Kayne Anderson Rudnick Investment Management LLC reduced its holdings in Eli Lilly by 5.6% during the first quarter, now owning 77,161 shares valued at approximately $63.7 million.
• Eli Lilly's recent earnings report showed an EPS of $6.31, significantly surpassing analyst expectations of $5.59, with a year-over-year revenue increase of 37.6%.
• The company recently announced a quarterly dividend of $1.50 per share, reflecting an annualized dividend yield of 0.8%.

Kayne Anderson Rudnick Investment Management LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 77,161 shares of the company's stock after selling 4,587 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC's holdings in Eli Lilly and Company were worth $63,728,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Redwood Investments LLC lifted its position in shares of Eli Lilly and Company by 0.5% in the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock worth $1,705,000 after buying an additional 12 shares during the last quarter. Hobbs Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after buying an additional 12 shares during the last quarter. Hixon Zuercher LLC lifted its position in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after buying an additional 12 shares during the last quarter. O Brien Wealth Partners LLC lifted its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after purchasing an additional 12 shares during the last quarter. Finally, Ascent Capital Management LLC lifted its position in Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Stock Up 0.1%

LLY stock opened at $710.7290 on Monday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $972.48. The company has a market capitalization of $672.68 billion, a price-to-earnings ratio of 46.45, a price-to-earnings-growth ratio of 0.99 and a beta of 0.44. The firm's 50-day moving average is $754.70 and its two-hundred day moving average is $789.97. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is currently 39.22%.

Insider Buying and Selling

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.